Surrogate markers of disease in mastocytosis

International Archives of Allergy and Immunology
C Akin, D D Metcalfe

Abstract

Measurement of surrogate mast cell-related products in blood or urine is often performed to assess disease extent in evaluating patients with mastocytosis. Serum tryptase and 24-hour urine histamine metabolites are the most commonly used surrogate markers of mastocytosis. In addition, several novel markers including soluble CD117 and soluble CD25 have been identified in recent studies. The utility and the pitfalls of each of these measurements are discussed.

Citations

Feb 7, 2013·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·K Brockow
Feb 15, 2013·Journal of Anesthesia·Norma J Klein, Shad Misseldine
May 26, 2005·Clinica Chimica Acta; International Journal of Clinical Chemistry·A W van Toorenenbergen, A P Oranje
Jan 25, 2003·Journal of Clinical Gastroenterology·Guang-Yu Yang, A Brian West
Feb 2, 2006·International Archives of Allergy and Immunology·Nataliya M Kushnir-SukhovDean D Metcalfe
May 18, 2011·International Archives of Allergy and Immunology·Peter ValentMichel Arock
Aug 30, 2008·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Feikje WesseldijkFreek J Zijlstra
May 25, 2007·Leukemia Research·Patricia AultMichael J Keating
Aug 26, 2006·Immunology and Allergy Clinics of North America·Peter Valent
Aug 22, 2003·British Journal of Haematology·Peter ValentDean D Metcalfe
Nov 22, 2008·European Journal of Clinical Investigation·N M Kushnir-SukhovD D Metcalfe
Dec 1, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·M LangeB Nedoszytko
Sep 19, 2015·Clinical Lymphoma, Myeloma & Leukemia·Douglas TremblayJohn Mascarenhas
Oct 17, 2003·Hematology/oncology Clinics of North America·Peter ValentDean D Metcalfe
May 4, 2004·Immunology and Allergy Clinics of North America·Knut Brockow
Dec 25, 2012·The Journal of Allergy and Clinical Immunology·Karin HartmannUlrike Raap
May 1, 2005·Expert Review of Clinical Immunology·Ido BacheletFrancesca Levi-Schaffer
Jan 31, 2017·Annual Review of Pathology·Dean D Metcalfe, Yoseph A Mekori
Sep 3, 2019·The Journal of Allergy and Clinical Immunology·Catherine R WeilerLawrence B Schwartz
Jul 19, 2019·The Journal of Allergy and Clinical Immunology. in Practice·Joseph M KulinskiHirsh D Komarow
Mar 26, 2003·Archives of Pathology & Laboratory Medicine·Ronald E Domen, Gerald A Hoeltge
Oct 28, 2004·Rapid Communications in Mass Spectrometry : RCM·Yaru SongYi-Ming Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Current Opinion in Allergy and Clinical Immunology
K Brockow, D D Metcalfe
International Archives of Allergy and Immunology
Karin Hartmann, Beate M Henz
© 2022 Meta ULC. All rights reserved